Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Enzalutamide). Same strength and form. Confirm the switch with your doctor or pharmacist.
Indications & Uses
Aresta 40 is indicated for:
Pharmacology
Enzalutamide is an androgen receptor inhibitor, and it works on several steps of the androgen receptor signaling pathway. It competes with androgens for binding to the androgen receptors. Because of this, the receptors can't move into the cell nucleus and can't interact with DNA.
A major metabolite, N-desmethyl enzalutamide, showed similar activity to enzalutamide in vitro. In vitro, enzalutamide reduced the growth of prostate cancer cells and caused them to die. In a mouse prostate cancer xenograft model, it also decreased tumor volume.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
The recommended dose of Enzalutamide is 160 mg taken by mouth once a day, with or without food. Swallow the capsules or tablets whole. Don't chew, dissolve or open the capsules, and don't cut, crush or chew the tablets.
Dosage Modifications for Adverse Reactions
If a patient has a ≥Grade 3 adverse reaction, or one they can't tolerate, Enzalutamide should be withheld for one week or until symptoms improve to ≤Grade 2. After that, treatment can restart at the same dose or at a reduced dose (120 mg or 80 mg) if warranted.
Strong CYP2C8 Inhibitors
Avoid giving Enzalutamide together with strong CYP2C8 inhibitors. If they can't be avoided, reduce the Enzalutamide dose to 80 mg once daily. If the strong inhibitor is later stopped, increase Enzalutamide back to the dose used before the inhibitor was started.
Strong CYP3A4 Inducers
Avoid giving Enzalutamide together with strong CYP3A4 inducers. If they can't be avoided, increase the Enzalutamide dose from 160 mg to 240 mg orally once daily. If the strong inducer is later stopped, decrease Enzalutamide to the dose used before the inducer was started.
Pediatric Use
The safety and effectiveness of Enzalutamide in children have not been established.
Renal Impairment
No dose change is recommended for patients with mild to moderate renal impairment.
Hepatic Impairment
No dose change is recommended for patients with mild, moderate or severe hepatic impairment.
Side Effects
The most common side effects seen in patients taking Enzalutamide (XTANDI) were asthenia or fatigue, back pain, hot flush, constipation, arthralgia, decreased appetite, diarrhoea and hypertension. Each of these happened in at least 10% of XTANDI patients, and each was seen at least 2% more often than in patients given placebo.
Cautions & Contraindications
Warnings & Precautions
Seizures occurred in 0.5% of patients receiving Enzalutamide. In patients who had factors that make a seizure more likely, the figure was 2.2%. If a patient has a seizure during treatment, stop Enzalutamide permanently. Posterior reversible encephalopathy syndrome (PRES): stop Enzalutamide. Hypersensitivity: stop Enzalutamide. Ischemic heart disease: manage the cardiovascular risk factors as well as possible. Stop Enzalutamide for Grade 3-4 events. Falls happened in 11% of patients and fractures in 10% of patients receiving Enzalutamide. Check each patient's risk of fracture and falls, and treat with bone-targeted agents according to established guidelines. Embryo-fetal toxicity: Enzalutamide can cause fetal harm and loss of pregnancy. Men whose female partners can become pregnant should be advised to use effective contraception.
Pregnancy & Breastfeeding
Enzalutamide has not been shown to be safe or effective in females. Animal reproductive studies and the way the medicine works suggest it can harm the fetus and cause loss of pregnancy. There are no human data on its use in pregnant females. When pregnant mice were given enzalutamide by mouth during organogenesis, it caused adverse developmental effects at doses lower than the maximum recommended human dose.
Safety and efficacy in females have not been established for breastfeeding either. Nobody knows whether enzalutamide passes into human milk, what it does to a breastfed infant, or whether it affects milk production. In lactating rats, enzalutamide and/or its metabolites were found in the milk.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Storage
Store Enzalutamide in a cool, dry place and keep it away from light. Keep it out of the reach of children.
Drug Interactions
Common questions about Aresta 40 40 mg
What is Aresta 40 40 mg Tablet?
Aresta 40 40 mg Tablet is a medicine that contains Enzalutamide. It is made by Jenphar Bangladesh Ltd. It belongs to the Cytotoxic Chemotherapy group of medicines.
What is Aresta 40 used for?
Aresta 40 is used for: Cancer.
What are the side effects of Aresta 40?
The most common side effects seen in patients taking Enzalutamide (XTANDI) were asthenia or fatigue, back pain, hot flush, constipation, arthralgia, decreased appetite, diarrhoea and hypertension. Each of these happened in at least 10% of XTANDI patients, and each was seen at least 2% more often than in patients given placebo.
Can I take Aresta 40 during pregnancy or while breastfeeding?
Enzalutamide has not been shown to be safe or effective in females. Animal reproductive studies and the way the medicine works suggest it can harm the fetus and cause loss of pregnancy. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store Aresta 40?
Store Enzalutamide in a cool, dry place and keep it away from light. Keep it out of the reach of children.
Can I take other medicines with Aresta 40?
Some medicines can interact with Enzalutamide, for example: Palbociclib, Gemfibrozil, Talazoparib, Rifampicin. Tell your doctor or pharmacist about every medicine you take.
Do I need a prescription for Aresta 40?
Aresta 40 is a prescription (Rx) medicine. Take it as your doctor advises.